InVisionFirst®-Lung
InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 37 genes relevant to the care of patients with advanced NSCLC. Covered for Medicare and other private insurance NSCLC patients who meet specific clinical criteria in the United States. InVisionFirst-Lung® is available world-wide for both commercial and research use.
Most popular related searches
electronic health record
cell-free DNA
clinical validation
clinical utility
biopsy testing
biopsy test
liquid biopsy
precision oncology
clinical trial
molecular diagnostic
Largest prospective molecular diagnostics study in NSCLC published up to date in JCO Precision Oncology
98% concordance
observed with matched tissue profiling
InVisionFirst-Lung provided access to comprehensive genetic profiling (CGP) when tissue was not available
26% more actionable alterations
detected versus standard-of-care tissue testing
Our technology brings high sensitivity and specificity to drive appropriate treatment choice
InVision® Platform can detect single nucleotide variants (SNVs), small insertions and deletions (InDels), copy number variant (CNVs), and structural variants (SV) such as fusions from plasma cell free DNA (cfDNA) with a detection range as low as 0.1% variant allele fraction with a mean read depth of 70,000.
Click here for InVisionFirst®-Lung clinical validation results and clinical utility data.
- Test results are delivered through a secure Clinician Portal
- The report includes genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials
- This report can be easily exported and added to most electronic health records (EHRs)